

About Whan In

Ever since its foundation in 1978, we have exerted utmost efforts to fulfill its social role of contributing to making a healthier society by producing and supplying good medicine. We currently produce various medicines, mainly specialized in Central Nervous System including specialized neuropsychiatric medications such as Anti-psychotics, anti-depressants, anti-epileptics, and also drugs for cardiovascular diseases and gastrointestinal disorders. To actively respond to the rapidly changing environment of pharmaceutical industry, we plan to focus further on R&D of new drugs and incrementally modified drugs and enhance our capacities, and at the same time place emphasis on entering the global market and discovering new growth engines. In implementing all innovation activities, all members of the company will comply with ethical management principles and the ethical code of conduct, and operate business in a transparent and fair manner through anti-corruption management system.

We will carry out our mission as a pharmaceutical company, our responsibility for stakeholders, dedication to customers and our social roles in an earnest manner, through which it aims to establish its position as an ever-growing trustworthy company.

We will continue creating new values based on differentiated R&D capacities and Open Innovation, and secure competitiveness in the global market to take a leap as a global health care company.

We will always consider the health of customers as our top priority, and will make the utmost efforts to lead the future pharmaceutical industry.

Company History


- 2019 Co-promotion Agreement with GSK KOREA (REQUIP, LAMICTAL, NARAMIG, IMIGRAN)
- 2018 Subsidiary Company, AMBRO B&P Co., Ltd was founded
- 2018 40th Foundation Anniversary Ceremony was held
- 2018 Exported to Turkey and Yemen
- 2017 Head Office Relocation
- 2017 Established PIC/S GMP plant at Anseong city
- 2016 Exported to Mongolia
- 1990~2013 Entered Co-promotion agreements with major pharmaceutical companies
- 1996 Listed on Korea Stock Exchange Market
- 1994 Established Central Research Laboratory
- 1987 Established KGMP plant at Anseong city
- 1978 Established as a private pharmaceutical company



Whan In's Strength

*Whan In – focused in CNS


Breaking down our sales revenue reveals that CNS accounts for 79%, CV is 6% and GI 6%, followed by Osteoporosis and Analgesics.



* Source: Official Announcement








*CNS Sales Breakdown by Sub-categories










Anti-psychotics is our main therapeutic area with 23% market share and our position is also very strong in Anti-epileptics, Anti-depressants and Tranquillizers.













* Source: IMS 2018 4Q
* Exchange rate: 1,100 KRW/USD













Whan In Product List

Therapeutic category	Generic name	Picture	(A)CTD	Zone IV b
Anti-psychotics	Risperidone Tab. 0.5, 1, 2, 3mg		○	○
	Aripiprazole Tab. 2, 5, 10, 15, 30mg		○	○
	Quetiapine fumarate Tab. 12.5, 25, 50, 100, 200, 300mg			○
	Olanzapine Tab. 2.5, 5, 10mg			○
	Chlorpromazine HCl Tab. 100mg			
	Haloperidol Tab. 1.5, 3, 5, 10, 20mg			
	Blonanserin Tab. 2, 4, 8mg		○	












Therapeutic category	Generic name	Picture	(A)CTD	Zone IV b
Anti-depressants	Escitalopram Tab. 5, 10, 15, 20mg			
	Paroxetine Tab. 20mg			○
	Mirtazapine Tab. 7.5, 15, 30mg			○
	Sertraline Tab. 50, 100mg			
	Fluoxetine Cap. 10, 20mg			○
	Imipramine HCl Tab. 25mg			
	Lithium carbonate Tab. 300mg			
	Trazodone HCl Cap. 25mg			
	Clomipramine HCl Cap. 25mg			

Whan In Product List

Therapeutic category	Generic name	Picture	(A)CTD	Zone IVb
Anti-epileptics	Carbamazepine CR Tab. 200mg		○	○
	Phenytoin Tab. 100mg			○
	Levetiracetam Tab. 250, 500, 1000mg		○	○
	Levetiracetam CR Tab. 500, 750mg			
	Lacosamide Tab. 50, 100, 150, 200mg			○
	Gabapentin Cap. 100, 300mg			
	Clonazepam Tab. 0.5mg			
	Pregabalin Cap. 25, 75, 150, 300mg		○	○
	Topiramate Tab. 25, 100mg		○	○
	Sodium valproate Tab. 300mg			○

Therapeutic category	Generic name	Picture	(A)CTD	Zone IVb
Nootropics	Choline Alfoscerate Tab. 400mg			
Anti-dementia drugs	Donepezil HCl Tab. 5, 10, 23mg		○	○
	Memantine HCl Tab. 10mg		○	○
	Memantine HCl OD Tab. 5, 10mg			
Anti-Parkinson drugs	Benzotropine mesylate Tab. 1, 2mg			
Anxiolytics & hypnotics	Alprazolam Tab. 0.25, 0.4, 0.5mg			○
	Triazolam Tab. 0.125, 0.25mg			
	Flunitrazepam Tab. 1mg			
	Lorazepam Tab. 0.5, 1mg			
	Chlordiazepoxide HCl Tab. 5, 10mg			
	Zolpidem tartrate Tab. 10mg			
	Tofisopam Tab. 50mg			

Whan In Product List

Therapeutic category	Generic name	Picture	(A)CTD	Zone IVb
Cardiovascular	Cilostazol 100mg / Ginkgo biloba ext. 80mg Tab.			
	Diltiazem HCl Tab. 30mg			
	Rosuvastatin Tab. 5, 10, 20mg			○
	Pitavastatin Calcium Tab. 2mg			
	Triflusal Cap. 300mg			
	Valsartan Tab. 80, 160mg			
	Clopidogrel Tab. 75mg			
Osteoporosis	Risedronate sodium Tab. 35mg			○
Anti-inflammatory Analgesics & others	Naproxen sodium Tab. 275mg			
	Micronized Etodolac Tab. 400mg			
	Celecoxib Tab. 100, 200mg			○

Therapeutic category	Generic name	Picture	(A)CTD	Zone IVb
Gastrointestinal drugs	Ranitidine Tab. 75, 150mg			
Anti-diabetic agents	Glimepiride 2mg / Metformin HCl Tab.			○
Anti-viral agent	Valaciclovir Tab. 500mg			
Anti-fungal	Terbinafine Tab. 500mg			
Anti-histamines	Olopatadine HCl Tab. 5mg			
Alcoholism treatment	Naltrexone HCl Tab. 25, 50mg			
ADHD agents	Methylphenidate HCl Tab. 5, 10mg			

R&D Pipeline

Whan In Pharmaceutical Research Institute endeavors to develop differentiated medications.

	Project Code	Dosage Form	Therapeutic Area	Development Stage (as of Aug. 2019)	Dossier Availability
IMD (Incrementally Modified Drug)	WIP-DF17	CR	Depression	Phase I (completed)	1Q 2020
	WIP-LX16	CR	Epilepsy	Phase I (pilot PK completed)	TBD
	WIP-RVX14	CR	Dementia	Phase III (IND approved)	2020
LAI (Long Acting Injection)	WIL-1901	Depot	Dementia	Pre-clinical (on-going)	1Q 2023
	WIL-1902	Depot	Parkinson's	Formulation (on-going)	TBD
	WIL-1903	Depot	Addiction	Formulation (on-going)	TBD
Generics	WIG-QX15	CR	Schizophrenia	BE study (o-going)	4Q 2019
	WIG-1810	Immediate Release	Epilepsy	Formulation (on-going)	3Q 2021
	WIG-PD16	CR	Schizophrenia	BE study (on-going)	2Q 220
	WIG-RG18	Immediate Release	Parkinson's	BE study (completed)	4Q 2019
	WIG-PE18	CR	Parkinson's	BE study (IND approved)	1Q 2021
	WIG-1809	Immediate Release	Parkinson's	BE study (IND approved)	4Q 2020
	WIP-MP15	CR	ADHD	BE study (on-going)	3Q 2020
	WIG-PRX18	CR	Pain	Formulation (on-going)	TBD
	WIG-MS16	ODT	Depression	BE study (completed)	Upon partner's request

Business Partnership

Whan In pursues the partnership with strong local distributors and develop Co-investment strategies for global market.



Export Countries (including registration stage)				
Mongolia	Vietnam	The Philippines	Hong Kong	Cambodia
Yemen	Georgia	Uzbekistan	Peru	Chile